Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck's IMPROVE-IT: FDA Panel Review Has Implications Beyond Zetia, Vytorin

This article was originally published in The Pink Sheet Daily

Executive Summary

Whether FDA agrees that results from ezetimibe cardiovascular outcomes study confirm the LDL hypothesis for non-statin drugs is of keen interest to sponsors of PSCK9 inhibitors and other novel lipid-lowering agents.

You may also be interested in...



PCSK9 Inhibitors May Feel Effects Of FDA Judgment On IMPROVE-IT

Agency's decision on cardiovascular risk reduction claims for Merck's Zetia and Vytorin may serve as a regulatory barometer for the magnitude and robustness of effect that will be expected in outcomes studies for other LDL-C-lowering agents.

Merck's IMPROVE-IT Study: Will Missing Data, Subgroups Hinder Zetia CV Claim?

FDA asks advisory committee to weigh impact of missing follow-up and 'notable differences' in subgroup treatment effects on company's request for broad cardiovascular benefit claim for Zetia and Vytorin.

Recent And Upcoming FDA Advisory Committee Meetings

Recent and upcoming FDA advisory committee meetings and a summary of topics covered.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS077979

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel